A detailed history of Vanguard Group Inc transactions in Ocugen, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 15,521,167 shares of OCGN stock, worth $15.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,521,167
Previous 11,999,551 29.35%
Holding current value
$15.4 Million
Previous $19.7 Million 22.25%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.18 - $1.98 $4.16 Million - $6.97 Million
3,521,616 Added 29.35%
15,521,167 $24.1 Million
Q1 2024

May 10, 2024

SELL
$0.5 - $1.83 $20,183 - $73,871
-40,367 Reduced 0.34%
11,999,551 $19.7 Million
Q4 2023

Feb 14, 2024

BUY
$0.36 - $0.57 $41,171 - $65,188
114,366 Added 0.96%
12,039,918 $6.86 Million
Q3 2023

Nov 14, 2023

BUY
$0.4 - $0.62 $47,682 - $73,908
119,207 Added 1.01%
11,925,552 $4.77 Million
Q2 2023

Aug 14, 2023

SELL
$0.45 - $0.88 $543,827 - $1.06 Million
-1,208,505 Reduced 9.29%
11,806,345 $6.38 Million
Q1 2023

May 15, 2023

BUY
$0.82 - $1.33 $947,679 - $1.54 Million
1,155,707 Added 9.75%
13,014,850 $11.1 Million
Q4 2022

Feb 10, 2023

BUY
$1.11 - $1.87 $174,926 - $294,695
157,591 Added 1.35%
11,859,143 $15.4 Million
Q3 2022

Nov 14, 2022

BUY
$1.75 - $3.1 $496,564 - $879,628
283,751 Added 2.49%
11,701,552 $20.8 Million
Q2 2022

Aug 12, 2022

BUY
$1.83 - $3.45 $935,576 - $1.76 Million
511,244 Added 4.69%
11,417,801 $25.9 Million
Q1 2022

May 13, 2022

BUY
$2.34 - $4.72 $704,487 - $1.42 Million
301,063 Added 2.84%
10,906,557 $36 Million
Q4 2021

Feb 14, 2022

SELL
$4.38 - $15.67 $1.18 Million - $4.21 Million
-268,393 Reduced 2.47%
10,605,494 $48.3 Million
Q3 2021

Nov 12, 2021

BUY
$6.36 - $8.51 $3.09 Million - $4.14 Million
486,356 Added 4.68%
10,873,887 $78.1 Million
Q2 2021

Aug 13, 2021

BUY
$5.52 - $15.68 $57.3 Million - $163 Million
10,387,531 New
10,387,531 $83.4 Million

Others Institutions Holding OCGN

About Ocugen, Inc.


  • Ticker OCGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,566,000
  • Market Cap $214M
  • Description
  • Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...
More about OCGN
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.